Sun Pharma to Acquire Concert Pharmaceuticals (CNCE) for $8 Per Share Plus CVR streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun.
Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure
Sun Pharmaceutical Industries Ltd and Concert Pharmaceuticals, Inc. have executed a definitive agreement under which Sun Pharma will acquire all outstanding shares of Concert through a tender offer.
Sun Pharmaceuticals is acquiring Concert Pharmaceuticals, a biotech whose lead program has positive data from two late-stage clinical trials in alopecia areata. The deal gives Sun Pharma a drug candidate that could match up against hair loss drugs from two big pharmaceutical companies.